top of page
Case Studies and Reviews
First Preclinical Study
Dr. Ko's first preclinical study was more successful than anyone could have imagined. This mouse model seeded 34 mice with hepatocellular carcinoma with 19 mice treated with 3BP and 15 untreated mice serving as controls. All 19 treated mice were completely cured and lived out a normal lifespan, while all 15 controls had to be euthanized.
Second Preclinical Study
Though the second preclinical study does not appear to be as dramatic or spectacular as the first, that understanding is far from true. In many ways, Dr. Ko feels that the significance of the second study was critical for her to validate the safety and potential toxicology of KAT ultimately for human use.
Third Preclinical Study
This preclinical study was in partnership with the University of Maryland in 2018 and tested KAT’s effectiveness in conjunction with Radiation Therapy (RT). These results have been particularly exciting, as it was designed to explore the effect of 3BP on tumor growth in non-small cell lung cancer.
First Human to Receive 3BP
This photograph of the first recipient of 3BP for cancer, Yvar Verhoeven, in this Case Report was poised with the novel anticancer agent, 3-bromopyruvate (3BP) and his favorite legendary immortal bird, phoenix. The picture was taken on his 18th birthday, September 09, 2009, at his home in the Netherlands, after his 7th treatment with 3BP. This was a very special day as he had been told that he would never make it to his 17th birthday.
Human Case Study - Melanoma
This sequence of photos are of a 70 Y/O Male with Melanoma. In 2017, a biopsy was taken of his forehead growth and while waiting for results, the patient began applying a KAT-soaked gauze daily to the open wound. The biopsy revealed it was melanoma and a follow up surgery was scheduled. However, when wound site was reopened, the melanoma was completely gone. This patient has been observed for five years with no evidence of recurrence.
99 Year Old Male - Bladder Cancer
Charles Phelps was diagnosed with bladder cancer in February 2018. HIs biopsy was delayed for several reasons, but showed high grade, aggressive urothelial cancer. The initial PET scan before KAT treatments began showed 3 areas in the bladder and one area in his lung. After bladder wash treatments were given, the PET scan showed his bladder was clear but there were three areas in his lung. After I.V. treatments along with bladder washes, the third PET scan showed only one area still visible in the lung but that area had reduced in size. This case demonstrates the clear safety of KAT in that it can be administered both in I.V. and bladder wash formulas for someone at almost 100 years of age. It would be very unlikely that Charles could have survived traditional chemotherapy or other toxic cancer treatments at his age. However, thanks to his KAT therapy, Charles remains alive and healthy today at 103 years of age.
Canine Report Cooper Hawk
March 5, 2022
This case report was submitted by Don McLean DVM at 965 Crockett Ridge Road, Norway, Me. 04268. Dr. McLean used only a 4-month, oral KAT treatment regimen for Cooper Hawk, a 13-year old male Alaskan Husky and reported a complete cure of Cooper's hard fixed sarcoma on midline of his proximal chest.
Canine Case Study Report
18 April 2022
This canine case study involved treating a dog (Chippy, 12 year-old spayed female Alaskan Husky) with IT injections for an anal sac adenocarcinoma. The formal cancer diagnosis was made in early August 2021 by Dr. B. Walker, DVM (Cape Horn Pet Clinic, Northumberland, NH). The dog received treatments that spanned an 8-month period (July 14, 2021 - March 8, 2022).
bottom of page